Syntara (ASX:SNT) has taken a significant step forward in the development of its next-generation topical anti-fibrotic therapy, announcing that its lead pan-lysyl oxidase inhibitor, SNT-9465, has completed a Phase 1a clinical trial and will now progress into a Phase 1b study in patients with hypertrophic scars. …
Syntara advances next-generation anti-fibrotic cream into Phase 1b trial
November 26, 2025 Australian Biotech
Latest Video
New Stories
-
MSD to bring vaccine distribution back in-house after 40-year partnership with CSL Seqirus
November 27, 2025 - - Latest News -
Pharmac announces 90-day dispensed quantities of HIV medicines
November 27, 2025 - - Latest News -
Landmark report warns Australia’s hospital pharmacy system is at an 'inflection point'
November 27, 2025 - - Latest News -
Australia releases first national estimate of women living with metastatic breast cancer
November 27, 2025 - - Latest News -
Imugene and JW Therapeutics join forces on first-in-class combination for solid tumours
November 27, 2025 - - Australian Biotech -
Algorae Pharmaceuticals secures new supply of chemotherapy for Australia through Dr Reddy’s partnership
November 27, 2025 - - Latest News -
An interview that reminds us of the missing discussion in Australia
November 27, 2025 - - Latest News